Clinical Trial

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Study acronym: DoMMino-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Protocol Amendment History 3 changes
notable Trial sites expanded: 20 -> 30 locations 2026-07-31
notable Trial sites expanded: 11 -> 20 locations 2026-06-03
notable Trial sites expanded: 2 -> 11 locations 2026-04-16
Trial Details
NCT Number NCT07096778
Lead Sponsor CellCentric Ltd.
Conditions Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Enrollment 100 participants
Start Date 2026-01-22
Primary Completion 2029-12-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30